Stifel raised the firm’s price target on Tango Therapeutics (TNGX) to $40 from $24 and keeps a Buy rating on the shares, citing increased conviction for the PRMT5 inhibitor + RAS(ON) inhibitor synergy in pancreatic ductal adenocarcinoma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics Overhauls Finance Leadership Amid Clinical Push
- Canaccord starts Tango Therapeutics with Buy on PRMT5 inhibitor
- Tango Therapeutics initiated with a Buy at Canaccord
- Tango Therapeutics price target raised to $21 from $14 at B. Riley
- Tango Therapeutics price target raised to $20 from $19 at Mizuho